ReviewMyManuscript logo
Review My ManuscriptAI-assisted pre-review
Illustrative AI review — based on a real open-access article (Shengliang Chen et al., BMC Cardiovascular Disorders, 2023; DOI: 10.1186/s12872-023-03478-3; License: CC-BY 4.0). Not a real journal decision.
Sample / illustrative report only — fictional neuro-oncology manuscript for UI demo. Not a real patient case, not a journal decision. Upload your own manuscript to receive a real review.
ANALYSIS REPORTFictional sample05.07.2026

Association of glycemic control with hypertension in patients with diabetes: a population-based longitudinal study

Font size:
View:

This is a concise overview. Switch to Full evaluation (Detailed) above for the complete report.

Key Points

  • 1Longitudinal analysis of 2,140 diabetic patients from a Chinese community health cohort examining HbA1c category and incident hypertension over a median 4-year follow-up; reverse causation risk, HbA1c measurement timing variability, and absent antihypertensive-use adjustment limit causal inference.

Major Issues

Methods: Antihypertensive medication initiation during follow-up is not modelled as a time-varying confounder; patients with poor glycaemic control may be prescribed antihypertensives earlier (protecting against the outcome) or later (masking blood pressure elevation), creating a competing events problem that biases the HbA1c–hypertension association.
Methods: HbA1c is measured at annual clinic visits only; within-person glycaemic variability (coefficient of variation, time-in-range) is not captured; a patient with HbA1c 7.8% at one visit may have substantially different integrated glucose burden compared to a patient with HbA1c 7.8% across all visits.
Methods / Results: Hypertension is ascertained from clinical coding without ambulatory blood pressure measurement (ABPM) validation; coding of hypertension in a community diabetes registry is subject to under-ascertainment bias (undiagnosed hypertension) and coding heterogeneity across participating clinics.
Discussion: The J-curve relationship between HbA1c and cardiovascular outcomes is not explored; the reference category (HbA1c ≤7%) includes patients at risk of hypoglycaemia-related cardiovascular events; a spline analysis would reveal whether the relationship is truly monotonic.

Priority Action Plan

HIGH IMPACT

Problem

Model antihypertensive medication initiation as a time-varying confounder using a marginal structural model; or redefine the hypertension outcome to make it independent of prescribing behaviour.

Why it matters

Antihypertensive use confounds the HbA1c–hypertension association in opposing directions; without adjustment, the direction and magnitude of the association remain uncertain.

Suggested fix

Model antihypertensive medication initiation as a time-varying confounder using a marginal structural model; or redefine the hypertension outcome to make it independent of prescribing behaviour.

HIGH IMPACT

Problem

Add restricted cubic spline analysis for continuous HbA1c to identify whether the relationship is monotonic or J-shaped; explore the clinically important question of whether intensive glycaemic control (HbA1c <6.5%) is associated with higher hypertension risk (through hypoglycaemia-mediated sympathetic activation).

Why it matters

The categorical analysis assumes a step-function relationship; the J-curve question is clinically critical and directly relevant to ADA/EASD treatment target guidelines.

Suggested fix

Add restricted cubic spline analysis for continuous HbA1c to identify whether the relationship is monotonic or J-shaped; explore the clinically important question of whether intensive glycaemic control (HbA1c <6.5%) is associated with higher hypertension risk (through hypoglycaemia-mediated sympathetic activation).

MEDIUM IMPACT

Problem

Report absolute 4-year hypertension incidence rates by HbA1c category and compute E-values for the primary HR to quantify robustness against unmeasured confounding.

Why it matters

Absolute risks and E-values are expected by cardiovascular epidemiology reviewers; they contextualise the HR in terms of public health impact and causal confidence.

Suggested fix

Report absolute 4-year hypertension incidence rates by HbA1c category and compute E-values for the primary HR to quantify robustness against unmeasured confounding.

Quick win: The longitudinal design and dose–response pattern are genuine strengths. The central revision is statistical: model antihypertensive use as a time-varying confounder and add a spline analysis for continuous HbA1c. These are achievable with the existing dataset and would substantially strengthen the paper's causal claims for internal medicine and diabetes journals.

Upload your manuscript
Open interactive sampleHow journal fit worksSample reports hubDesk-reject guides
Illustrative AI review sample — internal medicine | Review My Manuscript